Admissions:
Delistings:
Brand Architekts (BAR.L) delisted from AIM.
Brown Group (BWNG.L) delisted from AIM.
Jaywing (JWNG.L) delisted from AIM
Potential** Initial Public Offerings:
6 February: Media reports that The Beauty Tech Group, owner of CurrentBody, a brand of beauty technology, is considering a £350m London stock market listing. The Company describes itself as a global industry leader in home-use beauty technology, and is focused on products which use LED, radio frequency, microcurrent and laser treatments. The Beauty Tech Group saw revenues pass the £100m mark for the first time, up from £80m in 2023. Details, including the size of any primary share sale, have yet to be finalised.
6 February: GlobalData (DATA.L) has announced an intention to move to the Main Market from AIM. Timing is tbc.
6 February: Creightons (CRL.L) has announced an intention to move to AIM from the Main Market. Timing is subject to various approvals, but for 31 March.
Avingtrans 360p £119m (AVG.L)
The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors has today announced that its subsidiary Booth Industries, has secured a new £4.5m contract to supply pressure-rated fire doors for HS2. The contract expands upon Booth Industries' involvement in the HS2 project, following the £36m contract secured in September 2020 to supply cross passage doors for the London-to-West Midlands segment of the route. Booth will begin mass production of the cross-passage sliding doorsets in its 600m², production cell during 2025. Following the initial HS2 contract, Booth developed tested doors capable of withstanding high pressure shockwaves across more than 5 million cycles, delivering a design life exceeding 30 years. This proven innovation and expertise are now being applied to bespoke designs for the newly awarded pressure-door contract.
Contango Holdings 1.25p £9.5m (CGO.L)
The Company focused on unlocking value from the +2bn tonne Muchesu coal project in Zimbabwe has announced it has now received a further royalty payment of US$300,000. This brings the total royalty receipts to date under the previously reported Mineral Royalty Agreement with Huo Investments Limited to US$500,000. The balancing US$500,000 payment under the previously reported US$1,000,000 is expected to be made later this month. As previously reported, the Company is entering into a series of agreements with Huo Investments, including the MRA, a Revolving Facility Agreement of US$20,000,000, as well as entering into a change of ownership of Monaf Investments Limited, the subsidiary that holds the Muchesu Project. The Company is targeting signing the final Definitive Agreements in the current quarter, although as previously noted Huo Investments commenced material investment under the RFA during the second half of 2024 and has also commenced payments under the MRA.
Conroy Gold and Natural Resources 2.45p £1.3m (CGNR.L)
The mineral exploration Company today provided an update on the operational and strategic progress with its “Discs of Gold” project in Ireland. The re-logging programme for the Clontibret drill core is ongoing with work having commenced on the construction of a more robust 3D geological model beginning with the cross sections in the existing deposit where the re-logging is complete. This work contributes to the Company’s ongoing discussions with potential strategic and financial partners on defining and funding the next cycle of major investment in the “Discs of Gold” project. It also supports the Company’s planned application to the EU for recognition of Clontibret, with its antimony (Sb) potential, as a strategic project under the European Critical Raw Materials Act of 2024.
Empire Metals 8.45p £52.3m (EEE.L)
The resource exploration and development Company today announced the results from its recent mineral separation and hydrometallurgical testwork programme, carried out on core samples taken from the weathered cap that extends across the Pitfield Project, located in Western Australia. Development of the processing flowsheet continues at a rapid pace with several of the initial process stages now tested and proven to be effective for recovering anatase and rutile, the most abundant titanium minerals encountered in the mineralised weathered cap. The weathered cap, extending from surface to over 50m deep, is highly friable and amenable to low-cost scrubbing and desliming to remove fines before applying simple gravity recovery on the coarser fraction to produce a titanium mineral concentrate. Titanium was subsequently extracted from the flotation concentrates using an industry standard acid-bake water leach process with a 91% titanium extraction rate. Further optimisation of the flotation conditions is planned, aiming to increase recovery.
Gattaca 71.5p £22.25m (GATC.L)
The specialist staffing solutions business provides a trading update for the six months to January 2025. The total Net Fee Income (NFI) is expected to decline 3% to £18.8m with the contribution from Permanent down 10%. The Total Group headcount reduced by 12% YoY, with sales headcount reduced by 10% as it focuses on operational efficiency and resource allocation with headcount investment targeted at sectors showing growth opportunities. The guidance for FY July 25 adjusted profit before tax remains at £3m. Its net cash for the period is lower at £16.7m from £22.3m due to a reduction in trade creditors. An interim dividend is expected to be announced with results on 2 April.
ImmuPharma 3.95p £16.4m (IMM.L)
The specialist drug discovery and development Company has announced an equity fundraise of c.£2.91m, utilising existing authorities to allot shares. The fundraise comprises an oversubscribed placing to raise gross proceeds of £1.03m at a price of 3.75 pence per Ordinary Share and also a £1.875m subscription with current 6.5% shareholder Lanstead Capital Investors L.P at the Issue Price. The £1.875m gross proceeds of the Lanstead Subscription will be pledged by the Company pursuant to the Sharing Agreement with Lanstead. The Sharing Agreement entitles the Company to receive back those proceeds on a pro rata monthly basis over a period of seven months, commencing after the completion of the amended 2023 Lanstead Sharing Agreement, which is expected to be in May 2025, subject to adjustment upwards or downwards each month depending on the Company's share price at the time.
Ondo Insurtech 42.5p £45m (ONDO.L)
The provider of claims prevention technology for home insurers today announced a trading update. The adoption of Ondo's LeakBot solution by insurance companies has accelerated, driven primarily by successes in the US. Registered Customers are at approximately 135,000 as of 12 February 2025, with a projected increase to 150,000 by 31 March 2025. Annualised Revenue Run-Rate is projected to exceed £7.5m in Q4 FY2025, reflecting c.90% growth compared to Q4 FY2024 £4.0m. Full-Year Revenue to 31 March 2025: Estimated at £4.5m-£5m, approximately 70% growth versus FY 2024 £2.7m.
Oracle Power 0.018p £1.8m (ORCP.L)
The international project developer has recently announced that drilling is planned to re-commence in March 2025 at the Northern Zone Intrusive Hosted Gold Project, located just 25km east of Kalgoorlie, Western Australia. The next phase of drilling at Northern Zone aims to target and extend previous identified higher grade gold intercepts via a series of SW-NE orientated extensional lines using a nominal 20m spacing. A drilling contractor has been booked and will be mobilising to site in March 2025.
Physiomics 0.525p £1.1m (PYC.L)*
The mathematical modelling and data science Company supporting the development of new therapeutics and personalised medicine solutions has today announced that it has completed a placing, conditional on Admission, of, in aggregate, £430,000 at an issue price of 0.5p. The Company has also launched a retail offering via WRAP to the Company's existing shareholders to raise up to an additional £70,000 at the Placing Price, which will close on 17 February at 11am. Admission for the placing and WRAP shares is set for 8am on or around 18 February.
Thruvision 4.5p £7.75m (THRV.L)
The international provider of walk-through security technology updates on trading for Y/E March 2025. There are several significant opportunities, with a potential contract value of £15m, but for Y/E March 2026. Therefore, the impact on the current financials will be minimal, so revenue for the Y/E March 2025 will be in the range of £5-£6m, compared with the previous guidance of £9m. The Board continues to anticipate that the cash resources will last until approximately the end of May 2025. Since the announcement of the Strategic Review on 14 January 2025 discussions have been held, and are continuing, with a number of parties. It is hoped that one or more offers to either acquire the Group or to provide additional cash resources will be forthcoming although there can be no certainty that such offers will materialise.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
